Non-[18F]FDG PET in clinical oncology

Groves, Ashley M.; Win, Thida; Haim, S; Ell, Peter J.

doi:10.1016/s1470-2045(07)70274-7

Cited by 112 publications

(68 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[17][18][19][20] Cho penetrates cell membranes and is a natural constituent of blood. 21 In addition, Cho is a precursor of various metabolic pathways. In the brain, for example, choline is a substrate of choline containing phospholipids and of acetylcholine.…”

Section: Introductionmentioning

confidence: 99%

“…In the brain, for example, choline is a substrate of choline containing phospholipids and of acetylcholine. 22,23 However, in tumors Cho is integrated mainly into phospholipids, 21,22 a major constituent of cell membranes. Cho is incorporated into cell membranes by adenosine triphosphate (ATP) dependent phosphorylation and transformed by choline kinase in phosphocholine (PCho).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of in vivo15N MRS detection of hyperpolarized 15N labeled choline in rats

Cudalbu

Comment

Kurdzesau

et al. 2010

Phys. Chem. Chem. Phys.

102

125

View full text Add to dashboard Cite

The increase of total choline in tumors has become an important biomarker in cancer diagnosis. Choline and choline metabolites can be measured in vivo and in vitro using multinuclear MRS. Recent in vivo 13 C MRS studies using labeled substrates enhanced via dynamic nuclear polarization demonstrated the tremendous potential of hyperpolarization for real-time metabolic studies. The present study demonstrates the feasibility of detecting hyperpolarized 15 N labeled choline in vivo in a rat head at 9.4 T. We furthermore report the in vitro (172 AE 16 s) and in vivo (126 AE 15 s) longitudinal relaxation times. We conclude that with appropriate infusion protocols it is feasible to detect hyperpolarized 15 N labeled choline in live animals.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Feasibility of in vivo15N MRS detection of hyperpolarized 15N labeled choline in rats

Cudalbu

Comment

Kurdzesau

et al. 2010

Phys. Chem. Chem. Phys.

102

125

View full text Add to dashboard Cite

show abstract

“…Aerobic glycolysis is often accompanied by increased glucose uptake, and this phenomenon may be visualized in patient tumors using 18 F--deoxyglucose positron emission tomography (FDG--PET) scanning. FDG--PET scanning is used clinically as a staging tool for diverse cancer types, and experimental PET tracers can distinguish cancer from normal cells based on other aspects of cancer metabolism 6 . Differential uptake of 11 C--choline, 11 C--acetate, 11 Cmethionine, and 18 F--labeled amino acid analogs has also been demonstrated in some human cancers 6,7 .…”

mentioning

confidence: 99%

“…FDG--PET scanning is used clinically as a staging tool for diverse cancer types, and experimental PET tracers can distinguish cancer from normal cells based on other aspects of cancer metabolism 6 . Differential uptake of 11 C--choline, 11 C--acetate, 11 Cmethionine, and 18 F--labeled amino acid analogs has also been demonstrated in some human cancers 6,7 . Variable uptake of these molecules as well as FDG, and variable secretion of lactate, are all observed in human cancers even among tumors arising from the same tissue 6--9 .…”

mentioning

confidence: 99%

Targeting cancer metabolism: a therapeutic window opens

Heiden

2011

Nat Rev Drug Discov

1,280

1,076

View full text Add to dashboard Cite

PrefaceGenetic driver events in cancer activate signaling pathways that alter cell metabolism. Clinical evidence has linked metabolism with cancer outcomes.Together, this has raised interest in targeting metabolic enzymes for cancer therapy, but also concerns that these therapies would have unacceptable effects on normal cells. However, some of the first cancer therapies target the specific metabolic needs of cancer cells and remain effective agents used in the clinic today. Research to understand how changes in cell metabolism promote tumor growth has accelerated in recent years. This has refocused efforts on targeting metabolic dependencies of cancer cells, an approach with the potential to have a major impact on patient care.

show abstract

“…Cell surface receptors represent one type of target for imaging agents that provide information about signal pathway expression (Groves et al 2007). While the expression of the receptor alone is often an important parameter for staging and disease diagnosis, it does not directly indicate pathway activation.…”

Section: Cell Surface Receptorsmentioning

confidence: 99%

In vivo imaging of molecular targets and their function in endocrinology

Burdette

2008

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Imaging is one of the fastest growing fields of study. New technologies and multimodal approaches are increasing the application of imaging to determine molecular targets and functional processes in vivo. The identification of a specific target, transporter, or biological process using imaging has introduced major breakthroughs to the field of endocrinology primarily utilizing computed tomography, magnetic resonance imaging, ultrasonography, positron emission tomography, single-photon emission computed tomography, and optical imaging. This review provides a general background to the specific developments in imaging that pertains to in vivo function and target identification in endocrine-based diseases.

show abstract

Non-[18F]FDG PET in clinical oncology

Cited by 112 publications

References 55 publications

Feasibility of in vivo15N MRS detection of hyperpolarized 15N labeled choline in rats

Feasibility of in vivo15N MRS detection of hyperpolarized 15N labeled choline in rats

Targeting cancer metabolism: a therapeutic window opens

In vivo imaging of molecular targets and their function in endocrinology

Contact Info

Product

Resources

About